|PMut: a web-based tool for the annotation of pathological variants on proteins, 2017 update|
V López-Ferrando, A Gazzo, X De La Cruz, M Orozco, JL Gelpí
Nucleic acids research 45 (W1), W222-W228, 2017
|DEOGEN2: prediction and interactive visualization of single amino acid variant deleteriousness in human proteins|
D Raimondi, I Tanyalcin, J Ferté, A Gazzo, G Orlando, T Lenaerts, ...
Nucleic acids research 45 (W1), W201-W206, 2017
|Predicting disease-causing variant combinations|
S Papadimitriou, A Gazzo, N Versbraegen, C Nachtegael, J Aerts, ...
Proceedings of the National Academy of Sciences 116 (24), 11878-11887, 2019
|DIDA: A curated and annotated digenic diseases database|
AM Gazzo, D Daneels, E Cilia, M Bonduelle, M Abramowicz, ...
Nucleic acids research 44 (D1), D900-D907, 2016
|Understanding mutational effects in digenic diseases|
A Gazzo, D Raimondi, D Daneels, Y Moreau, G Smits, S Van Dooren, ...
Nucleic acids research 45 (15), e140-e140, 2017
|Whole-Exome Sequencing Analysis of the Progression from Non–Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma|
F Pareja, DN Brown, JY Lee, A Da Cruz Paula, P Selenica, R Bi, ...
Clinical Cancer Research 26 (14), 3682-3693, 2020
|Multilevel biological characterization of exomic variants at the protein level significantly improves the identification of their deleterious effects|
D Raimondi, AM Gazzo, M Rooman, T Lenaerts, WF Vranken
Bioinformatics 32 (12), 1797-1804, 2016
|Cancer-causative mutations occurring in early embryogenesis|
F Pareja, RN Ptashkin, DN Brown, F Derakhshan, P Selenica, ...
Cancer discovery 12 (4), 949-957, 2022
|APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas|
P Selenica, A Marra, NJ Choudhury, A Gazzo, CJ Falcon, J Patel, X Pei, ...
Annals of oncology 33 (12), 1284-1295, 2022
|TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer|
EM da Silva, P Selenica, M Vahdatinia, F Pareja, A Da Cruz Paula, ...
NPJ Breast Cancer 7 (1), 43, 2021
|Morphologic and genomic characteristics of breast cancers occurring in individuals with Lynch syndrome|
CJ Schwartz, EM da Silva, A Marra, AM Gazzo, P Selenica, VK Rai, ...
Clinical Cancer Research 28 (2), 404-413, 2022
|Using game theory and decision decomposition to effectively discern and characterise bi-locus diseases|
N Versbraegen, A Fouché, C Nachtegael, S Papadimitriou, A Gazzo, ...
Artificial intelligence in medicine 99, 101690, 2019
|210O Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy (ET)+/-CDK 4/6 inhibition (CDK4/6i) in estrogen receptor …|
A Marra, A Gazzo, A Gupta, P Selenica, EM Da Silva, F Pareja, X Pei, ...
Annals of Oncology 33, S632, 2022
|Genetic characterisation of adult primary pleomorphic uterine rhabdomyosarcoma and comparison with uterine carcinosarcoma|
CW Ashley, A Da Cruz Paula, L Ferrando, R Gularte‐Mérida, ...
Histopathology 79 (2), 176-186, 2021
|Whole‐exome sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma|
TM D'Alfonso, F Pareja, A Da Cruz Paula, M Vahdatinia, A Gazzo, ...
The Journal of Pathology: Clinical Research 7 (2), 113-120, 2021
|MYC amplification segment-size mutual exclusivity analysis with other oncogenic events in a pan-cancer sequencing cohort.|
M Repetto, AL Richards, MF Chen, Y Zhu, P Selenica, A Gazzo, P Lee, ...
Journal of Clinical Oncology 41 (16_suppl), 3073-3073, 2023
|KIT genetic alterations in breast cancer|
M Vahdatinia, F Derakhshan, ADC Paula, H Dopeso, A Marra, AM Gazzo, ...
Journal of Clinical Pathology, 2022
|Abstract LB517A: The role of EGFR in resistance to tucatinib and its therapeutic implications|
J Veeraraghavan, FT Liao, T Gordon, P Selenica, S Nanda, L Qin, Y Zhu, ...
Cancer Research 82 (12_Supplement), LB517A-LB517A, 2022
|Abstract PD8-06: Acquired resistance to tucatinib is associated with EGFR amplification in HER2+ breast cancer (BC) models and can be overcome by a more complete blockade of …|
J Veeraraghavan, S Bose, R Mistry, P Selenica, S Nanda, L Qin, A Gazzo, ...
Cancer Research 82 (4_Supplement), PD8-06-PD8-06, 2022
|Abstract PD1-06: Apobec mutagenesis is a pervasive feature of poor prognosis breast cancer associating with ESR1 wild type, endocrine resistant disease|
A Marra, A Gazzo, P Selenica, X Pei, A Gupta, F Pareja, G Curigliano, ...
Cancer Research 82 (4_Supplement), PD1-06-PD1-06, 2022